Sir, Afatinib is an irreversible tyrosine kinase inhibitor that blocks the epidermal growth factor receptor. It has been recently approved as a first-line treatment for patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutations. It has been demonstrated in randomized trials that progression-free survival is significantly higher with afatinib than with other existing treatments. Several adverse reactions have been reported in patients treated with epidermal growth factor receptor inhibitors, most affecting the gastrointestinal and respiratory tracts and the skin. Although cutaneous side effects are usually mild, they may be cosmetically unacceptable to patients. [1] A 68-year-old woman was diagnosed with stage IV lung adenocarcinoma; epidermal growth factor receptor mutation status of the tumor was positive. She was a non-smoker and her past medical history was significant for hypertension, hypercholesterolemia and hypothyroidism. She was treated with pemetrexed (500 mg/m 2 /intravenous) and cisplatin (75 mg/m 2 / intravenous) as palliative therapy and there was no tumor progression noted after 4 months. Despite four cycles of chemotherapy, she developed a left pleural effusion and millimetric nodules in both lung fields. The treatment was switched to afatinib (40 mg orally once daily) and was tolerated well except for a moderate oral mucositis. After 4 months of afatinib therapy, she complained of excessive growth of both eyelashes and eyebrows [ Figure 1 ]. She was on no other treatment and denied the application of any topical product. Physical examination revealed trichomegaly and excessive growth of the eyebrow. The patient was reassured and tolerated this adverse effect well, requiring only regular trimming of the eyelashes and eyebrows over the next few months.
Epidermal growth factor receptor inhibitors are associated with multiple cutaneous side effects such as acneiform eruptions, paronychia, mucositis, pruritus, xerosis, telangiectasia and hyperpigmentation. Hair changes such as alopecia, facial hypertrichosis, eyebrow growth and trichomegaly have also been reported. [2, 3] Trichomegaly is an abnormal growth of eyelashes causing discomfort. This side effect has been described in association with cetuximab, erlotinib, gefitinib, and panitumumab. [4] The epidermal growth factor receptor is involved in the development and differentiation of the hair follicle. This receptor is expressed in keratinocytes of the hair follicle and regulates the transformation from anagen to catagen. Its inhibition can stimulate the formation of a disorganized hair follicle with abnormal hair growth. Trichomegaly usually appears 10-14 weeks after the beginning of treatment with these medications. [5] It is usually a mild side effect that does not require discontinuation of the drug. Nevertheless, in some patients it may be a cosmetic and ophthalmological problem because keratitis, conjunctivitis or trichiasis may occur. [4] Trichomegaly is usually reversible with discontinuation of treatment. It is not yet known if epidermal growth factor receptor inhibitor-associated trichomegaly occurs only in patients whose tumor is responding to treatment. We were unable to find any previous reports of this adverse effect.
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Sir, Cutaneous lymphoid hyperplasia is also known as cutaneous lymphocytoma. Cutaneous lymphoid hyperplasia belongs to the spectrum of cutaneous pseudolymphomas which are lymphocytic infiltrates with clinical or histological features that mimic cutaneous lymphomas but follow a benign course. Most of these are predominantly composed of B cells. [1] Cutaneous lymphoid hyperplasia is usually idiopathic but sometimes is associated with arthropod bites, scabies, infections (Borrelia burgdorferi is the most commonly identified agent in Europe), drugs, tattoo pigments and vaccine residues. [1, 2] It is more frequent in middle aged Caucasian women (sex ratio F:M 3:1). [1] Adverse effects of vaccination are usually benign and transient, generally consisting of mild erythema or pain at the site of injection. Less commonly, chronic papules or subcutaneous nodules may appear which have been related to aluminum-adsorbed vaccines. [1, 2] Some rare cases of cutaneous lymphoid hyperplasia secondary to hyposensitization vaccines have been reported. [3] A 26-year-old Caucasian woman presented with itchy nodules located at the lateral side of both arms. The itchy nodules had appeared 12 years back but had recently become increasingly itchy. She was allergic to olive tree pollen and the nodules had developed at the site of hyposensitization vaccine injections against olive tree pollen that she had received during childhood. The vaccination course consisted of an induction period during which she received a weekly subcutaneous injection for 3 months followed by monthly injections for 3 years. These nodules appeared 3 years after commencing the vaccination course; for this reason, the treatment was discontinued.
Physical examination revealed five subcutaneous nodules that were mobile, firm and showed excoriation marks [ Figure 1a ]. The nodules were painless and the overlying skin had an erythemato-violaceous hue. The complete blood count and biochemistry tests were normal. Serology for Borrelia burgdorferi was negative. A punch biopsy revealed a nodular lymphoid infiltrate with enlarged germinal centers located in the deep dermis and hypodermis [ Figure 1b ] where apoptotic bodies were also observed [ Figure 1c ]. Giant multinucleated cells were also seen. [Figure 2a ].
